Clinical pharmacokinetics of oral CCNU (Lomustine)

@article{Lee2004ClinicalPO,
  title={Clinical pharmacokinetics of oral CCNU (Lomustine)},
  author={F. Y. F. Lee and Paul Workman and J. Trevor Roberts and Norman M. Bleehen},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={14},
  pages={125-131}
}
SummaryThe plasma pharmacokinetics of orally administered CCNU (130 mg/m2) were studied in four patients using reversed-phase high-performance liquid chromatography (HPLC) analysis. Parent CCNU was not detected in the plasma of any of the patients, probably due to complete conversion to monohydroxylated metabolites during the ‘first pass’ through liver and gut. However, two monohydroxylated metabolites, trans-4-hydroxy CCNU and cis-4-hydroxy CCNU, were found at high concentrations, the relative… 
Pharmacokinetics of tauromustine in cancer patients
TLDR
Thrombocytopenia was the dose-limiting toxicity of TCNU; the reduction of platelet counts appeared to be linearly related to the log dose and Cmax and AUC values.
Interaction of nitroimidazole sensitizers with drug metabolizing enzymes--spectral and kinetic studies.
  • F. Y. Lee, P. Workman
  • Medicine
    International journal of radiation oncology, biology, physics
  • 1986
TLDR
The present results provide strong evidence that the mechanism involves binding to liver microsomal cytochrome P-450, leading to inhibition of CCNU metabolism, and that altered pharmacokinetics also occur in man.
Preliminary Metabolism of Lomustine in Dogs and Comparative Cytotoxicity of Lomustine and Its Major Metabolites in Canine Cells
The nitrosourea drug lomustine is used clinically for treating a wide variety of malignancies, most commonly brain tumors and lymphoma. Lomustine undergoes hydrolysis in vivo to form isomeric
Hepatotoxicity Associated with CCNU (Lomustine) Chemotherapy in Dogs
TLDR
It is suggested that CCNU can cause delayed, cumulative dose-related, chronic hepatotoxicity that is irreversible and can be fatal.
The hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in rats
TLDR
It is suggested that CCNU causes a bimodal hepatotoxicity in rats: an early and prolonged ductal injury and a delayed anti-liver cell microtubule toxicity.
CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
TLDR
CCNU-associated toxicity in dogs is common, but is usually not life threatening, and most commonly in the treatment of lymphoma, mast cell tumours, histiocytic tumours and epitheliotropic lymphoma.
Synthesis of trans- and cis-4'-hydroxylomustine and development of validated analytical method for lomustine and trans- and cis-4'-hydroxylomustine in canine plasma.
TLDR
The present study developed and validated a simple high-performance liquid chromatography method with a one-step liquid-liquid extraction procedure to detect and quantify lomustine and its two monohydroxylated metabolites (trans- and cis-4'-hydroxylomUSTine) in canine plasma for future pharmacokinetic studies.
Interactions Between Antiretrovirals and Antineoplastic Drug Therapy
TLDR
Existing data regarding the metabolic fate of the anthracyclines doxorubicin and daunorUBicin suggest that clinically detrimental interactions would not be expected with coadministered HAART, and further research delineating the combined safety and pharmacokinetics of antiretrovirals and antineoplastic therapy is necessary.
Dose Adaptation of Antineoplastic Drugs in Patients with Liver Disease
TLDR
It is concluded that there are currently not enough data for safe use of cyctostatics in patients with liver disease and pharmaceutical companies should be urged to provide kinetic data (especially hepatic extraction data) for the classification of such drugs.
Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes
TLDR
The results of these studies indicate that the metabolism of the drugs concerned is possibly altered in poor metabolizers of debrisoquine and requires further investigation to study their specific routes of biotransformation.
...
1
2
3
4
...

References

SHOWING 1-10 OF 39 REFERENCES
Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.
TLDR
Modification of the pharmacokinetics may be a major contributory factor in the enhancement of CCNU cytotoxicity by large single doses of MISO in vivo.
Misonidazole and CCNU: further evidence for a pharmacokinetic mechanism of chemosensitization and therapeutic gain.
TLDR
It is found that tumour response is well correlated with tumour peak CCNU concentration, and it is suggested that this is the explanation for the therapeutic gain.
Comparison of the properties of metabolites of CCNU.
TLDR
Six isomeric metabolites of N -(2-chloroethyl- N ′-(hydroxycyclohexyl- N -nitrosoureas) have been compared and are consistent with the hypothesis that the biological effects observed following the administration of CCNU are due to a large extent to the major metabolites with lesser effects contributed by the minor metabolites.
Nitroimidazoles as modifiers of nitrosourea pharmacokinetics.
  • F. Y. Lee, P. Workman
  • Medicine
    International journal of radiation oncology, biology, physics
  • 1984
TLDR
It seems that for a pharmacokinetic interaction to occur between a nitroimidazole and a nitrosourea, both the modifier and the cytotoxic agent must have a requisite degree of lipophilicity.
Chemosensitization by lipophilic nitroimidazoles.
TLDR
There appears to be a therapeutic gain at low doses of CCNU of about the same magnitude as produced by 2.5 mmol kg-1 misonidazole, and the production of this gain at relativelyLow doses of BENZO is of possible clinical significance.
Physiologic disposition of 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (CCNU) and 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (MeCCNU) in man
TLDR
The physiologic disposition of radioactive‐labelled CCNU and MeCCNU was studied in patients receiving these drugs as part of their early clinical trial and the degradation of both drugs appears to be extremely rapid since the intact drug could not be detected in any plasma, CSF, or urine sample.
The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model.
TLDR
Pretreatment with phenobarbital reduced the toxic death rate of CCNU at 40, 60, 90, or 120 mg/kg to less than 10% and after four daily doses of PB prior to the same dose ofCCNU, respectively.
In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
TLDR
In this animal tumour model the combination of CCNU and MISO appears to lead to a potential gain by a factor of approximately 1.7, which is similar to that seen in intramuscularly growing KHT sarcomas.
Effect of pretreatment with phenobarbital or SKF 525A on the toxicity and antitumor activity of lomustine.
TLDR
Treatment with phenobarbital or SKF 525A did not result in a therapeutic advantage for CCNU, unlike pretreatments with the sensitizer misonidazole, and the combination of the conventional chemotherapeutic agent lomustine and the nitroimidazoles radiation sensitizers can lead to an improved therapeutic result.
Distribution of bratton-marshall-positive material in mice following intravenous injections of nitrosoureas
TLDR
Assay of selected samples by high-pressure liquid chromatography revealed that the colorimetric assay for BCNU was specific in that the two assays gave equivalent results, and a fair correlation was observed between the Cxt values for tissues and the toxic and/or antitumor effects at those sites.
...
1
2
3
4
...